Last reviewed · How we verify
Capecitabine & Oxaliplatin
Capecitabine is converted to 5-fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while oxaliplatin forms DNA cross-links to prevent replication.
Capecitabine is converted to 5-fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while oxaliplatin forms DNA cross-links to prevent replication. Used for Metastatic colorectal cancer, Gastric cancer, Breast cancer (adjuvant and metastatic settings).
At a glance
| Generic name | Capecitabine & Oxaliplatin |
|---|---|
| Also known as | Capecitabine and Oxaliplatin |
| Sponsor | Samsung Medical Center |
| Drug class | Antimetabolite and platinum-based chemotherapy combination |
| Target | Thymidylate synthase (capecitabine/5-FU); DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is a prodrug that undergoes hepatic and tumor-selective conversion to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and incorporates into RNA and DNA to disrupt nucleotide synthesis. Oxaliplatin is a third-generation platinum compound that forms interstrand and intrastrand DNA cross-links, preventing DNA replication and transcription. Together, this combination (XELOX regimen) provides synergistic cytotoxic activity against rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
- Gastric cancer
- Breast cancer (adjuvant and metastatic settings)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Diarrhea
- Nausea/vomiting
- Hand-foot syndrome
- Peripheral neuropathy
- Mucositis
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (PHASE3)
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (PHASE2)
- Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy (NA)
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (PHASE2)
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) (PHASE1, PHASE2)
- Pan Tumor Rollover Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine & Oxaliplatin CI brief — competitive landscape report
- Capecitabine & Oxaliplatin updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI